

Guilherme Perini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1069606/publications.pdf>

Version: 2024-02-01

56
papers

617
citations

933447

10
h-index

610901

24
g-index

56
all docs

56
docs citations

56
times ranked

1102
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	1.6	195
2	BCL-2 as therapeutic target for hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2018, 11, 65.	17.0	136
3	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
4	How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 103-110.	0.2	33
5	Brentuximab Vedotin in CD30+ Lymphomas. <i>Biologics in Therapy</i> , 2013, 3, 15-23.	1.8	24
6	KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8005-8005.	1.6	24
7	Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients – An analysis from the Brazilian Hodgkin Lymphoma Registry. <i>International Journal of Cancer</i> , 2018, 142, 883-890.	5.1	17
8	Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. <i>Hematological Oncology</i> , 2018, 36, 189-195.	1.7	15
9	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018, 132, 228-228.	1.4	14
10	BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2021, 22, 66.	3.0	13
11	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 590-599.	5.2	10
12	Primary central nervous system lymphoma: what a neurologist/neurosurgeon should know?. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 254-257.	0.8	9
13	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2021, 138, 306-306.	1.4	5
14	Hepatosplenic gamma-delta T-cell lymphoma, disseminated intravascular coagulation, and systemic mastocytosis: an unusual presentation for a rare disease. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 693-4.	0.3	5
15	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
16	Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. <i>Blood</i> , 2020, 136, 12-12.	1.4	4
17	Baseline total metabolic tumor volume (TMTV) application in Hodgkin lymphoma: a review article. <i>Clinical and Translational Imaging</i> , 2022, 10, 273-284.	2.1	4
18	Alemtuzumab in the reversal of encephalopathy associated with hypereosinophilic syndrome. <i>British Journal of Haematology</i> , 2009, 147, 592-592.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Hodgkin's disease and pregnancy: case series and proposal for treatment protocol. Einstein (Sao Tj ETQq1 1 0.784314 rgBT JOverloc	0.7	2
20	Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL). Blood, 2020, 136, 18-21.	1.4	2
21	Weight Gain in the First 10 Days after Hematopoietic Stem Cell Transplantation (HSCT) Is a Risk Factor for Early Mortality. Blood, 2014, 124, 2471-2471.	1.4	2
22	Genomic Profile of Patients with Triple Negative (JAK2, CALR and MPL) Essential Thrombocythemia and Primary Myelofibrosis. Blood, 2014, 124, 4589-4589.	1.4	2
23	Progressive multifocal leukoencephalopathy in a patient with relapsed chronic lymphocytic leukemia treated with Ibrutinib. Hematology, Transfusion and Cell Therapy, 2020, , .	0.2	2
24	Clinicopathological Features and Outcomes of EBV Positive and Negative DLBCL: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). Blood, 2021, 138, 1442-1442.	1.4	2
25	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
26	Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study. Blood, 2020, 136, 19-20.	1.4	2
27	Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia. Einstein (Sao Paulo, Brazil), 2011, 9, 190-195.	0.7	1
28	Lymphocyte:Monocyte Ratio At The Start Of Conditioning Regimen Is Associated With Survival Post-Autologous Stem Cell Transplantation (ASCT) For Lymphoma and Myeloma. Blood, 2013, 122, 3327-3327.	1.4	1
29	Imatinib Treated Chronic Myelogenous Leukemia Concomitant with Multiple Myeloma. Is There a Relationship?. Blood, 2010, 116, 5005-5005.	1.4	1
30	A Novel Prognostic Index for Patients with EBV-DLBCL NOS: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). Blood, 2021, 138, 1436-1436.	1.4	1
31	PET-CT Quantitative Parameter Delta Suvmax As a Predictor of Early Relapse in Patients with Difuse Large B-Cell Lymphoma. Blood, 2021, 138, 4580-4580.	1.4	1
32	Follicular Lymphoma in Latin America: Real-World Experience from 763 Patients. Blood, 2020, 136, 12-13.	1.4	1
33	Impact of Time to Lymphocyte Recovery on Survival Post Autologous Stem Cell Transplantation.. Blood, 2010, 116, 4540-4540.	1.4	0
34	Risk Factors and Mortality Associated with CMV Reactivation Post Autologous Stem Cell Transplantation.. Blood, 2010, 116, 4531-4531.	1.4	0
35	Magnetic Resonance Imaging (MRI) Detection of Iron Overload In Patients with Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 4960-4960.	1.4	0
36	Magnetic Resonance Imaging (MRI) Detection of Iron Overload In Patients with Myelodysplastic Syndrome (MDS).. Blood, 2011, 118, 3827-3827.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Early Impact Of a Nurse-Based Program To Reduce The Time From First Fever To Antibiotic Infusion In Neutropenic Patients In a Oncohematological and Bone Marrow Transplantation Unit In Brazil. <i>Blood</i> , 2013, 122, 1704-1704.	1.4	0
38	Absolut Lymphocyte Count At Diagnosis Is Predictive Of Survival In Patients With Classical Hodgkin Lymphoma: A Retrospective Multicenter Brazilian Study. <i>Blood</i> , 2013, 122, 4236-4236.	1.4	0
39	Fluid Accumulation During The Early Phases Of Hematopoietic Stem Cell Transplantation (HSCT) Is Associated With An Increased Risk Of Mortality and Complications. <i>Blood</i> , 2013, 122, 4572-4572.	1.4	0
40	Should Albumin Be Considered a Prognostic Factor For Brazilian Patients Diagnosed With Classical Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 5049-5049.	1.4	0
41	Multicentric Bone Involvement As Presentation Of Late Relapse In a Patient With Hairy Cell Leukemia (HCL). <i>Blood</i> , 2013, 122, 5285-5285.	1.4	0
42	Characteristics Of 1455 Brazilian Lymphoma Patients Enrolled In Abrale (Brazilian Leukemia and) Tj ETQq0 0 0 rgBT, /Overlock_10 Tf 50 5	1.4	0
43	The Presence of ASXL1 Mutations As Well As a Total Number of Myeloid Driver Mutations Higher Than Two Is Strongly Associated with the Diagnosis of Primary Myelofibrosis As Opposed to Essential Thrombocythemia. <i>Blood</i> , 2014, 124, 4595-4595.	1.4	0
44	Post-Transplant Lymphoproliferative Disorders in Transplant Recipients: 14-Yr Experience at the Hospital Israelita Albert Einstein - Brazil. <i>Blood</i> , 2016, 128, 3047-3047.	1.4	0
45	Autologous Stem Cell Transplantation (ASCT) As Upfront Treatment in Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Comparative Analysis in Clinical Trials Setting. <i>Blood</i> , 2016, 128, 2272-2272.	1.4	0
46	Early MMF Discontinuation Is an Effective and Safe Measure to Decrease CMV Reactivation in Patients Submitted to Unmanipulated Haploidentical Transplant with Post-Cy Immunosuppression. <i>Blood</i> , 2016, 128, 2216-2216.	1.4	0
47	A Simplified Novel Prognostic Score to Predict Early Mortality and Disease Progression in Patients with Aggressive Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 1404-1404.	1.4	0
48	Serum Albumin and Neutrophil-to-Lymphocyte Ratio, Two Independent Factor Predicting Survival in Patients with Follicular Lymphoma: A Multi-Institutional Retrospective Cohort of 741 FL, from the Latin American Lymphoproliferative Study Group (GELL). <i>Blood</i> , 2021, 138, 4515-4515.	1.4	0
49	Updated Analysis Confirms Sustained Poor Prognosis of COVID-19 in Patients with Lymphoma in Latin America: A Cohort of 160 Patients from Gell. <i>Blood</i> , 2021, 138, 2520-2520.	1.4	0
50	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S22-S29.	0.2	0
51	Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). <i>Blood</i> , 2021, 138, 2516-2516.	1.4	0
52	Proposal of a Novel Latin American International Prognostic Index (LATAM-IPI) for Diffuse Large B-Cell Lymphoma (DLBCL) By the Grupo Para El Estudio De Linfoproliferativos En Latino-America (GELL). <i>Blood</i> , 2020, 136, 25-27.	1.4	0
53	COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
54	Cell of Origin Impacts $\hat{\tau}$ ’suvmax Cutoff for Prediction of Relapse in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL). <i>Blood</i> , 2020, 136, 20-23.	1.4	0
56	Implementation of a Public Lymphoma Clinic in a Private Hospital in Brazil: Challenges and Impact of Delayed Diagnosis in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2020, 136, 13-14.	1.4	0